NUMERO: #20220315

Título: Ki67 AND CD138/SYNDECAN-1 IMMUNOEXPRESSION IN AMELOBLASTOMAS

Nome do Apresentador: Allan Vinícius MARTINS-DE-BARROS

Categoria do Trabalho: Trabalhos Aprovados para Disponibilização em Vídeo (ADV)

Área Temática: Patologia Oral

Resumo: Objective: To assess Ki67 and CD138/Syndecan-1 immunoexpression and investigate possible predictors of disease-free survival in patients with ameloblastomas. Study Design: This is a retrospective cohort study. The study population consisted of individuals diagnosed with conventional ameloblastoma. The clinical, imaging, histopathological and immunohistochemical expression of Ki67 and CD138/syndecan-1 proteins were analyzed. Kaplan-Meier analysis was used to estimate disease-free survival rates. The log-rank test and Cox proportional hazards regression were used to identify predictors of disease-free survival. A statistical significance level of 5% was established. Results: Thirty-one individuals diagnosed with ameloblastoma were included in this study. Tumors were more frequent in the 2nd and 3rd decades of life and in brown-skinned individuals (58.1%), with a male to female ratio of 1.5:1. Only the initial treatment modality was statistically associated with a better prognosis in univariate (p = 0.026) and multivariate (p = 0.021) analyses, with a Hazard Ratio of 22.14 (95%CI = 1.60-305.73), favoring radical treatment. Conclusion: None of the clinical, imaging, histopathological or immunohistochemical characteristics analyzed were associated with disease-free survival in ameloblastomas. However, cases that received radical surgical treatment had a lower risk of recurrence.

Autor 1:  Allan Vinícius MARTINS-DE-BARROS

E-mail 1:  [email protected]

Autor 2:   Leorik Pereira da SILVA

E-mail 2:  [email protected]

Autor 3 :  Lucas Nascimento RIBEIRO

E-mail 3:  [email protected]

Autor 4:  Stefânia Jeronimo FERREIRA

E-mail 4:  [email protected]

Autor 5:  Emanuel Dias de Oliveira e SILVA

E-mail 5:  [email protected]

Autor 6:  Fábio Andrey da Costa ARAÚJO

E-mail 6:  [email protected]

Autor 7:  Marianne de Vasconcelos CARVALHO

E-mail 7:  [email protected]